申请人:Sandoz Pharm. Corp.
公开号:US04625039A1
公开(公告)日:1986-11-25
6-trans-indol-2-yl-ethenyl)-4-hydroxy-tetrahydro-2H-pyran-2-ones of formula I are obtained by a multi-step reaction involving the procedure: ##STR1## wherein p.sup.1 is trisubstituted silyl protective group, and Z is a 2-indolyl radical which may be bear at the 4, 5, 6 and 7-positions up to two substituents such as alkyl, alkoxy, halo and CF.sub.3, and at either one the 1 or 3-positions a substituted or unsubstituted phenyl; and at the other an assymetric alkyl, cycloalkyl or aralkyl radical. Compounds I, e.g. (E)-trans-6-[1'-methyl-3'-(4"-fluorophenyl)indol-2'-ylethenyl]3,4,5,6 -tetrahydro-4-hydroxy-2H-pyran-2-one(4R,6S); are useful as anti-atheroselerotic agents.
公式I的6-反式-吲哚-2-基乙烯)-4-羟基-四氢-2H-吡喃-2-酮通过涉及以下程序的多步反应得到:##STR1##其中p.sup.1是三取代硅烷保护基,Z是一个2-吲哚基团,可以在4、5、6和7位承载多达两个取代基,例如烷基、烷氧基、卤素和CF.sub.3,在1或3位之一是取代或未取代苯基;在另一位是一个不对称的烷基、环烷基或芳基基团。 化合物I,例如(E)-反式-6-[1'-甲基-3'-(4"-氟苯基)吲哚-2'-基乙烯基]3,4,5,6-四氢-4-羟基-2H-吡喃-2-酮(4R,6S);可用作抗动脉粥样硬化药物。